



# Is antimicrobial multidrug resistance really a great problem?

---

*Winfried V. Kern*

Division of Infectious Diseases  
Department of Medicine  
University Hospital Freiburg, Germany






A problem for whom ?

ESCMID Online Lecture Library  
© by author

## ... a problem for whom?

- the traveller to India (with intestinal ESBL-*E.coli* colonization) ?
- dto. with urinary tract infection (pyelonephritis) two weeks after returning from the trip ?
- the 90-yr old male with prostatic cancer, confusion, and bacteriuria (?infection?) due to VRE + carbapenem-resistant *P. aeruginosa* ?
- the 73-yr old male with vertebral osteomyelitis due to MRSA ?
- the alloSCT recipient with KPC2 bacteremia and shock ?

# ... a problem for whom ?



- the traveller to India (with intestinal ESBL-*E.coli* colonization) ?
- dto. with urinary tract infection (pyelonephritis) two weeks after returning from the trip ?
- the 90-yr old male with prostatic cancer, confusion, and bacteriuria (?infection?) due to VRE + carbapenem-resistant *P. aeruginosa* ?
- the 73-yr old male with vertebral osteomyelitis due to MRSA ?
- the alloSCT recipient with KPC2 bacteremia and shock ?

- A problem for my microbiologist ?

... perhaps, if he ...

did not inform all those involved early enough about the carbapenem resistance, and the patient died



■ A problem for my microbiologist ?

... perhaps, if he ...  
did not inform all those involved early  
enough about the carbapenem  
resistance, and the patient died

ESCMID Online Lecture Library  
© by author



- A problem for my microbiologist ?


... perhaps, if he ...  
did not inform all early enough about  
the carbapenem resistance, and the  
patient died

- A problem for my ID consultant ?

... perhaps, if he ...

asked me whether KPC2 would in fact mean K.p*pneumoniae* resistant to cephalosporins of the 2nd generation





- A problem for my ID consultant ?

... perhaps, if he ...


asked me whether KPC2 would in fact mean K.p*neumoniae* resistant to cephalosporins of the 2nd generation

- A problem for me ?

... as an ID physician working on MDR and on antibiotic strategies:

■ A problem for me ?

... as an ID physician working on MDR and on antibiotic strategies:



NO

- A problem for me ?

... as an ID physician consulting in the ICU on this particular KPC2 patient:



- A problem for me ?

... as an ID physician consulting in the ICU on this particular KPC2 patient:

**OMNICARBAPENEX**

**EVERYMYCIN**


**ANTIFLOXACIN**

**ANYBACTAM**

...

**NO**

- A problem for the patient ?



... probably yes, if ...

the *Klebsiella* had a meropenem MIC of  $>32 \mu\text{g/mL}$ , and the doctor (intensivist or hematologist !! ??) prescribed (... modern ..) high-dose (3x2 g) meropenem with colistin 3x1 mio units per day (.... old-style ...)



- A problem for the hospital?

... probably yes, if ...

the *Klebsiella* spread unrecognized to wards and affected patients vulnerable to gram-negative infection

... and ...

there was no ID service available  
tasked with optimized treatment



- A problem for society ?

... probably yes, if ...

everybody used for almost all acutely ill patients initial empirical therapy with a carbapenem



# ... in more general terms

- MDR is a great problem for the most severely ill and for society in the future
  - more deaths, limiting the progress of modern medicine
  - more efforts (more ID & CM among other things) and cost

ESCMID Online Lecture Library  
© by author

# ... in more general terms

- MDR is a great problem for the most severely ill and for society in the future
  - more deaths, limiting the progress of modern medicine
  - more efforts (more ID & CM among other things) and cost
- MDR is also an opportunity
  - better understanding of mechanisms of (co-)resistance development
  - better definition of clinical breakpoints (I hate  $S + R$ ) and recognized more need for clinical validation

# ... in more general terms

- MDR is a great problem for the most severely ill and for society in the future
  - more deaths, limiting the progress of modern medicine
  - more efforts (more ID & CM among other things) and cost
- MDR is also an opportunity
  - better understanding of mechanisms of (co-)resistance development
  - better definition of clinical breakpoints (I hate  $S + R$ ) and recognized more need for clinical validation
  - → „intelligent“ prescribing ?

